{Reference Type}: Journal Article
{Title}: Effectiveness of leuprolide acetate administered monthly compared to three-monthly in the treatment of central precocious puberty: evaluation at the end of treatment.
{Author}: Thaneetrakool T;Aroonparkmongkol S;Numsriskulrat N;Supornsilchai V;Wacharasindhu S;Srilanchakon K;
{Journal}: Front Endocrinol (Lausanne)
{Volume}: 15
{Issue}: 0
{Year}: 2024
{Factor}: 6.055
{DOI}: 10.3389/fendo.2024.1390674
{Abstract}: <B>UNASSIGNED: </B>Gonadotropin-releasing hormone (GnRH) analogs are the standard treatment for central precocious puberty (CPP). Although there are numerous varieties of GnRH agonists, the effectiveness of 1-monthly compared with 3-monthly Leuprolide acetate is still restricted. The objective of this study was to evaluate the outcomes of CPP treatment with Leuprolide acetate at a 1-monthly dosage of 3.75 mg, in comparison to a dosage of 11.25 mg administered every 3 months.<BR><B>UNASSIGNED: </B>This retrospective cohort study involved 143 girls diagnosed with CPP with 72 of them receiving the monthly treatment regimen and 71 receiving the 3-monthly treatment regimen. Anthropometric measurements were compared at the start and end of the therapy. The rates and level of LH suppression were assessed six months after therapy.<BR><B>UNASSIGNED: </B>The regimen administered every 3 months showed more significant suppression of LH. The 3-monthly group showed lower actual height and degree of bone age advancement at the end of therapy. However, the predicted adult height (PAH) remained comparable in both groups.<BR><B>UNASSIGNED: </B>The 3-monthly treatment showed greater hormonal and growth suppression effects, but there was no significant difference in PAH between the two groups.